首页> Neurology and therapy> Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance.

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance.

导出 LinkOut

翻译打印收藏纠错

第一作者： Takashi,Yamamura

第一单位： Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8511, Japan. yamamura@ncnp.go.jp.

作者： Takashi,Yamamura ^[1] ; Noriko,Isobe ^[2] ; Izumi,Kawachi ^[3] ; Chiyoko,Nohara ^[4] ; Yusei,Miyazaki ^[5] ; Minami,Tomita ^[6] ; Yuta,Kamei ^[6] ; Katsuhisa,Yamashita ^[7] ; Jin,Nakahara ^[8] ; Ichiro,Nakashima ^[9] ; Kazuo,Fujihara ^[10]

作者单位： Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8511, Japan. yamamura@ncnp.go.jp. ^[1] Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan. ^[2] Department of Neurology, Brain Research Institute, Niigata University, Niigata, 951-8585, Japan.;Medical Education Center, Niigata University School of Medicine, Niigata, 951-8510, Japan. ^[3] Department of Neurology, Tokyo Metropolitan Ebara Hospital, Tokyo, 145-0065, Japan. ^[4] Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Sapporo, 063-0005, Japan. ^[5] Drug Safety Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan. ^[6] Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan. ^[7] Department of Neurology, Keio University School of Medicine, Tokyo, 160-8582, Japan. ^[8] Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, 983-8512, Japan. ^[9] Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.;Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, 963-8563, Japan. ^[10]

关键词 Adverse drug reactions Anti–IL-6 receptor antibody Glucocorticoids Infections Long-term Neuromyelitis optica spectrum disorder Post-marketing surveillance Relapse Safety Satralizumab

DOI 10.1007/s40120-025-00799-7

PMID 40999180

发布时间 2025-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Neurology and therapy

2025年14卷6期

2429-2451页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Neurology and therapy

2025年14卷6期

2429-2451页

检索历史清除

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance.

Neurology and therapy

相似文献

同项目论文

Neurology and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance.

Neurology and therapy

相似文献

同项目论文

Neurology and therapy

相关期刊

检索历史清除